Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 0.57 |
| ▸ | MMP9 | P14780 | 11/20 | 0.57 |
| ▸ | MMP3 | P08254 | 7/20 | 0.57 |
| ▸ | MMP13 | P45452 | 5/20 | 0.57 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 5/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7223468 | 0.89 | MMP2 (0.69) | MMP2MMP9MMP3MMP13PLA2G7 | |
| SCHEMBL7392933 | 0.88 | MMP2 (0.45) | MMP2MMP9MMP3MMP13PLA2G7 | |
| SCHEMBL6788599 | 0.81 | MMP2 (0.47) | MMP2MMP9MMP3MMP13PLA2G7 | |
| SCHEMBL7224275 | 0.80 | MMP2 (0.54) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7232717 | 0.78 | MMP2 (0.59) | MMP2MMP9MMP3MMP13PLA2G7 | |
| SCHEMBL7080614 | 0.77 | MMP2 (0.42) | MMP2MMP9MMP3MMP13PLA2G7 | |
| SCHEMBL7224457 | 0.76 | MMP3 (0.46) | MMP2MMP9MMP3MMP13PLA2G7 | |
| SCHEMBL7231531 | 0.74 | MMP2 (0.59) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL4820309 | 0.72 | PLA2G7 (0.46) | MMP2MMP9MMP3MMP13PLA2G7 | |
| SCHEMBL4820321 | 0.72 | PLA2G7 (0.46) | MMP2MMP9MMP3MMP13PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605604-B1 | Tumour necrosis factor alpha release inhibitors; efficiency treatment of cancers, rheumatic diseases, arthritis, ulcers, atherosclerosis, asthma | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |